FABP4 is a small cytoplasmic protein expressed abundantly in adipocytes and macrophages, where it buffers and traffics fatty acids, coordinating lipid storage, lipolysis, and inflammatory signaling. Over the past two decades it has attracted growing attention as an adipokine—a hormone-like molecule released from fat tissue—whose circulating levels track closely with obesity, insulin resistance, and cardiovascular risk. In adults with PCOS, several studies have reported elevated FABP4 concentrations, but the adolescent population has remained largely unexplored. That gap matters, because adolescence is precisely the window in which PCOS first declares itself and in which early intervention could alter long-term metabolic trajectories. The new research, led by Bahadır Codal and colleagues across hospitals and universities in Türkiye, set out to determine whether FABP4 could serve as both a metabolic correlate and a diagnostic marker in this younger cohort.

The study was designed as a prospective observational investigation involving 88 adolescents aged 10 to 19 years, evenly divided between 44 girls diagnosed with PCOS and 44 healthy controls. Diagnosis was made according to the 2023 international ESHRE/ASRM criteria, the most recent consensus framework for identifying PCOS across the lifespan. Each participant underwent a comprehensive clinical, anthropometric, and biochemical workup, including measurements of body mass index, androgen levels, fasting glucose and insulin, and derived indices of insulin resistance such as HOMA-IR. Serum FABP4 concentrations were quantified using an enzyme-linked immunosorbent assay, the standard immunoassay technique that relies on antibody-based capture and detection to produce a quantitative readout of protein concentration in blood.

The headline finding was unambiguous: median circulating FABP4 levels were significantly higher in adolescents with PCOS than in controls, at 5.74 nanograms per milliliter versus 3.59 nanograms per milliliter, a difference that achieved strong statistical significance with a p-value below 0.001. In other words, girls with PCOS carried roughly 60 percent more of this fat-derived protein in their bloodstream than their peers. But the researchers went further, asking whether this elevation simply reflected differences in body weight or whether it carried information independent of adiposity. Using multivariable linear regression, a statistical technique that estimates the independent contribution of each variable while holding the others constant, they found that PCOS status itself, along with body mass index and insulin resistance as measured by HOMA-IR, each contributed to higher FABP4 concentrations.

This triad of associations—PCOS status, BMI, and insulin resistance—fits neatly with the established biology of FABP4. The protein is secreted by hypertrophied adipocytes and by macrophages infiltrating inflamed fat depots, and its circulating levels rise as fat tissue expands and as insulin signaling deteriorates. In PCOS, insulin resistance is a central pathophysiologic thread, driving compensatory hyperinsulinemia that in turn stimulates ovarian androgen production. The observation that FABP4 tracks with HOMA-IR in adolescents suggests that the protein may serve as a readout of the metabolic disturbance that underlies the reproductive phenotype, capturing a dimension of the disease that androgen measurements alone do not fully represent.

The diagnostic question was addressed with a more sophisticated statistical armamentarium. Because the outcome of interest—PCOS diagnosis—is binary, the team employed Firth’s penalized logistic regression, a method designed to produce stable estimates in small samples where conventional maximum-likelihood logistic regression can fail or produce inflated coefficients. This analysis identified two variables independently associated with PCOS: the free androgen index, or FAI, a calculated measure of bioavailable testosterone that reflects hyperandrogenism, and FABP4 itself. That a fat-derived adipokine stood alongside the classic hormonal marker of the disease is the finding most likely to capture the attention of clinicians and researchers alike.

To translate these associations into clinically meaningful performance metrics, the researchers constructed receiver operating characteristic curves, the standard framework for evaluating how well a continuous biomarker discriminates between diseased and healthy individuals. A FABP4 threshold of 4.08 nanograms per milliliter yielded an area under the curve of 0.849, with 81.8 percent sensitivity and 75.0 percent specificity. In practical terms, an AUC of 0.849 indicates good—not perfect—discrimination, meaning the test correctly ranks a randomly chosen PCOS patient above a randomly chosen control in about 85 percent of paired comparisons. The sensitivity figure suggests the marker would miss roughly one in five true cases at this cutoff, while the specificity figure implies a meaningful rate of false positives if used alone.

Perhaps the most clinically relevant result emerged when FABP4 was combined with the free androgen index. Adding FABP4 to FAI improved the model’s discrimination substantially, with a change in AUC of 0.133 that was statistically significant at p equals 0.001. Crucially, this improvement persisted even after adjustment for body mass index, indicating that FABP4 contributes metabolic information that is not merely a proxy for body fatness. The authors interpret this as evidence that FABP4 provides complementary metabolic context when read alongside androgen markers—a framing that is deliberately cautious and appropriate for a biomarker still in its validation infancy.

Indeed, the study’s limitations are clearly acknowledged and worth emphasizing. The cohort of 88 participants is modest, and the case-control design, while efficient, cannot establish whether elevated FABP4 precedes the development of PCOS or is a consequence of it. The authors themselves note that BMI-matched studies, investigations that characterize body composition in detail rather than relying on BMI alone, and external validation in independent cohorts are all needed before FABP4 can be considered a clinically generalizable adjunctive biomarker in adolescent PCOS. Prior literature in adults has been mixed on this point, with some studies finding FABP4 associations that dissolve once obesity is properly controlled, and the new adolescent data, while encouraging, do not yet resolve that uncertainty.

Nevertheless, the study represents a meaningful step forward in a field where objective tools are badly needed. Diagnosing PCOS in adolescents has real consequences: delayed diagnosis allows metabolic dysfunction—insulin resistance, dyslipidemia, and long-term cardiovascular risk—to progress unchecked, while premature diagnosis can lead to unnecessary treatment and anxiety during a life stage when physiology is still settling. A biomarker that captures the metabolic dimension of the syndrome, complements hormonal testing, and performs well in a teenage population could eventually help clinicians navigate this diagnostic tightrope with greater confidence. For now, FABP4 should be viewed as a promising signal rather than a ready-made test, but the convergence of adipose biology, insulin resistance, and ovarian function that it represents may prove to be one of the more illuminating threads in the ongoing effort to understand PCOS where it begins—in adolescence.

Subject of Research: Circulating FABP4 as a metabolic biomarker for adolescent polycystic ovary syndrome

Article Title: Circulating Fatty Acid-Binding Protein 4 (FABP4) in Adolescents with Polycystic Ovary Syndrome: Metabolic Correlates and Diagnostic Performance

Article References: Codal, B., Kurt, A., Kaplan, H., Çakır, A., Hızlı, B., & Özler, M. R. (2026). Circulating Fatty Acid-Binding Protein 4 (FABP4) in Adolescents with Polycystic Ovary Syndrome: Metabolic Correlates and Diagnostic Performance. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02189-2

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02189-2

Keywords: PCOS, FABP4, adolescents, biomarkers, insulin resistance, hyperandrogenism, adipokines, free androgen index, ROC analysis, metabolic syndrome, reproductive endocrinology, HOMA-IR

The radioligand at the center of the study, [177Lu]Lu-P15-073, is a lutetium-177-labeled bisphosphonate. Bisphosphonates are compounds with a natural affinity for regions of active bone remodeling, where they bind to hydroxyapatite mineral. Because metastatic lesions in bone typically trigger intense local bone turnover, radiolabeled bisphosphonates accumulate preferentially at these sites, allowing the beta-minus radiation emitted by lutetium-177 to irradiate tumor cells embedded in the skeletal niche while sparing most healthy tissue. The companion imaging agent [68Ga]Ga-P15-073, labeled with the positron emitter gallium-68, allows clinicians to visualize where the therapeutic compound will lodge before committing to treatment, a theranostic pairing familiar from the success of prostate-specific membrane antigen-targeted radioligand therapy in prostate cancer.

The study’s authors set out to investigate an underappreciated dimension of this approach. The efficacy of bone-seeking radiopharmaceuticals, they argued, depends not only on radiation dosimetry, the traditional calculus of how much dose reaches tumor versus healthy organs, but also on the biological stability of the skeletal microenvironment itself. High-dose beta irradiation from [177Lu]Lu-P15-073, they hypothesized, might damage the bone niche in ways that inadvertently promote cancer progression. To test this, the team built an intratibial xenograft model, implanting human A549 lung adenocarcinoma cells directly into the tibia of experimental animals, and paired the model with quantitative proteomics to map, molecule by molecule, how the bone microenvironment responded to the therapeutic radiation.

The results revealed a sobering pattern. Although the radioligand showed sustained retention in the implanted bone tumors, confirming that the agent effectively targets skeletal lesions, animals receiving radioligand monotherapy fared worse than expected. At the experimental endpoint, the monotherapy group carried a higher pulmonary metastatic burden, meaning more lung cancer colonies had taken root in the lungs. Proteomic and structural analyses pointed toward a mechanism: the therapeutic radiation was associated with osteoclastogenesis, the formation and activation of the bone-resorbing cells that dismantle skeletal matrix, and with lipid-metabolic reprogramming in the bone microenvironment, marked by upregulation of the proteins FABP4 and PLIN1. These molecular shifts were accompanied by cortical bone degradation and, ultimately, by increased seeding of metastases in the lungs.

The lipid biology here is particularly intriguing. FABP4, a fatty acid-binding protein, and PLIN1, which coats intracellular lipid droplets, are classic markers of adipocyte differentiation and lipid accumulation. Their upregulation suggests that radiation reshaped the metabolic character of the bone niche, potentially enriching it with lipid-laden cells of the sort known to provide metabolic support to disseminated tumor cells. In the vicious cycle of bone metastasis, tumor-driven and treatment-driven osteolysis releases growth factors stored in bone matrix, fueling tumor growth further, while the resorbed architecture weakens the skeleton and opens routes for cancer cells to escape into circulation and colonize distant organs such as the lungs.

Having identified the mechanism, the researchers tested a mechanistically driven countermeasure: concurrent inhibition of RANKL, the receptor activator of nuclear factor kappa-B ligand. RANKL is the master signaling molecule that drives osteoclast differentiation and activation, and blocking it is already a clinically validated strategy for protecting bone in patients with metastatic disease. The anti-RANKL antibody denosumab is widely used to prevent skeletal-related events in cancer care. In the preclinical experiments, adding RANKL blockade to the radioligand regimen attenuated the radiation-associated osteoclastogenesis, blunted the lipid-metabolic reprogramming, and preserved skeletal integrity, effectively holding the bone niche together while the radiation attacked the tumor.

The impact on clinically meaningful outcomes was substantial. Pulmonary metastasis developed in only 25 percent of animals receiving the combination, compared with 87.5 percent of those treated with radioligand monotherapy and 75 percent of controls. Median survival also increased significantly, exceeding 50 days in the combination group versus 37.5 days in the monotherapy group, a difference the authors report as statistically significant with a P value below 0.01. In a disease context where bone metastases of lung cancer carry a bleak prognosis and few effective options, a treatment combination that both keeps the skeleton intact and curbs distant spread represents an unusually encouraging preclinical signal.

The study also extended into the clinic, albeit in a preliminary way. The team analyzed imaging data and early outcomes from a registered cohort of patients with bone-metastatic lung cancer, drawing on the clinical trial of lutetium-177-labeled phosphonates registered as ChiCTR2300077313 in November 2023. Translational morphological imaging showed heterogeneous remodeling patterns across treated lesions: a representative lesion in a patient exposed to denosumab, the RANKL inhibitor, showed signs of osteogenic repair, with new bone formation healing the damaged architecture, while a representative lesion treated with radioligand alone displayed progressive osteolysis, the characteristic moth-eaten destruction of bone. Although these clinical observations are preliminary and the human cohort was small, they mirror the biology observed in the animal models and lend translational weight to the combination hypothesis.

The authors are careful to frame their conclusions as associations and rationale rather than proof. Radiation-driven osteolysis and lipid reprogramming, they write, may represent factors that limit the efficacy of bone-targeted monotherapy, and concurrent RANKL inhibition may help stabilize the skeletal microenvironment and reduce the pulmonary metastatic burden observed in this model. The findings, they conclude, provide a preclinical rationale for further evaluation of RANKL inhibition alongside bone-seeking radioligands. Such measured language is appropriate for a study whose human component is exploratory, and the registered trial will be the venue in which the strategy faces the rigor of prospective clinical testing.

Nevertheless, the conceptual contribution of the work may prove as important as any single result. It challenges the field to think beyond dosimetry when designing bone-targeted radiopharmaceuticals, and to treat the bone microenvironment not as passive scenery but as an active, modifiable participant in treatment response. If radiation can inadvertently remodel the niche into a metastasis-promoting state, then protecting that niche may be as essential as delivering the dose itself. For patients with lung cancer that has invaded the skeleton, where the disease is incurable and skeletal complications compound an already difficult prognosis, a rational pairing of a bone-seeking radioligand with an osteoclast-blocking antibody offers a genuine path forward, and one that leverages drugs already on pharmacy shelves.

Subject of Research: Combining RANKL inhibition with bone-targeted radioligand therapy for lung cancer bone metastases

Article Title: RANKL inhibition potentiates bone-targeted radioligand therapy in lung cancer metastases: a translational study

Article References: Zhao, R., Deng, Y., Liang, W., Xu, M., Lv, J., Zhang, J., Wang, J., Liang, W., Zhou, C., Yu, P., Li, J., Zhu, L., Kung, H. F., & Wang, X. (2026). RANKL inhibition potentiates bone-targeted radioligand therapy in lung cancer metastases: a translational study. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09021-0

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09021-0

Keywords: radioligand therapy, lung cancer, bone metastases, RANKL inhibition, lutetium-177, bisphosphonates, osteoclastogenesis, denosumab, bone microenvironment, lipid metabolic reprogramming, FABP4, theranostics